首页> 外文期刊>Drug delivery. >Formulation and investigation of pilocarpine hydrochloride niosomal gels for the treatment of glaucoma: intraocular pressure measurement in white albino rabbits
【24h】

Formulation and investigation of pilocarpine hydrochloride niosomal gels for the treatment of glaucoma: intraocular pressure measurement in white albino rabbits

机译:用于治疗青光眼的盐酸纤维素尼罗芥术语的制剂和调查:白苋兔的眼压测量

获取原文

摘要

The present study was focused on investigating niosomal gels loaded with cholinergic drug; pilocarpine HCl, for prolonged precorneal residence time and improved bioavailability for glaucoma treatment. Pilocarpine HCl niosomes were prepared using various nonionic surfactants (span 20, span 60 and span 80), in the presence of cholesterol in different molar ratios by ether injection method. The selected formulations were incorporated into carbopol 934 and locust bean gum-based gels. TEM analysis confirmed that niosomes formed were spherical in shape and has a definite internal aqueous space with uniform particle size. Formulation F4 composed of span 60 and cholesterol (1:1) gave the highest entrapment (93.26?±?1.75%) and slower release results after 8?hours (Q8h?=?60.35?±?1.87%) among other formulations. The in-vitro drug permeation studies showed that there was a prolonged release of drug from niosomal gels as compared to niosomes itself. Considering the in-vitro drug release, niosomal gel formulation G2 was the best among the studied formulations. The release data were fitted to an empirical equation, which indicated that the release follows non-Fickian diffusion mechanism. The stability study revealed that incorporation of niosomes in gel increased their stability than the niosome itself. No signs of redness, inflammation, swelling or increased tear production were observed over the study period for tested formulation by Draize’s test. The intraocular pressure (IOP) lowering activity of G2 formulation showed relative bioavailability 2.64 times more than bioavailability of marketed Pilopine HS? gel. These results suggest that the niosomal gels containing pilocarpine HCl are promising ocular carriers for glaucoma treatment.
机译:本研究重点是调查用胆碱能药物负载的憩室凝胶;柳甘油HCL,用于延长的预甲型停留时间和改善青光眼处理的生物利用度。使用各种非离子表面活性剂(跨度20,跨度60和跨度80)在不同摩尔比的胆固醇中通过醚注入方法在不同的摩尔比的情况下制备皮脂甘油HCl憩室。将所选制剂掺入Carbopol 934和蝗虫豆胶基凝胶中。 TEM分析证实,形成的NIOSOMES形状是球形的,并且具有具有均匀粒度的内部含水空间。制剂F4由跨度60和胆固醇(1:1)组成,给出了最高的夹带(93.26?±1.75%),8?小时(Q8h?=Δ60.35?±1.87%)后较慢的释放结果。体外药物渗透性研究表明,与NiosomeS本身相比,患有梭菌凝胶的延长释放的药物。考虑到体外药物释放,Niosomal凝胶制剂G2是研究的制剂中最好的。释放数据适用于经验方程,表明释放遵循非Fickian扩散机制。该稳定性研究表明,凝胶中的术语掺入它们的稳定性比定位本身增加了它们的稳定性。通过Draize的试验,在研究期间没有观察到在研究期间进行发红,炎症,肿胀或增加的撕裂产量的迹象。 G2制剂的眼压(IOP)降低活性显示相对生物利用度比销售的Pilopine HS的生物利用度大2.64倍?凝胶。这些结果表明,含有Pilocarpine HCl的憩室凝胶是对青光眼治疗的眼镜载体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号